Nichtalkoholische Fettlebererkrankung

[1]  A. Tannapfel,et al.  Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025 , 2022, Zeitschrift fur Gastroenterologie.

[2]  C. Guja,et al.  Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies , 2022, Journal of clinical medicine.

[3]  E. Fröhlich,et al.  Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease , 2022, Metabolites.

[4]  H. El‐Serag,et al.  Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes , 2022, Digestive Diseases and Sciences.

[5]  C. Khoo,et al.  Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. , 2022, The Journal of clinical endocrinology and metabolism.

[6]  E. Roeb,et al.  Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy , 2022, Journal of clinical medicine.

[7]  E. Roeb.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review , 2021, Visceral Medicine.

[8]  M. Stepanova,et al.  Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  A. Gavin,et al.  Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation , 2021, JHEP reports : innovation in hepatology.

[10]  H. Tilg,et al.  Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals , 2020, Gut.

[11]  E. Roeb.  Non-alcoholic fatty liver diseases: current challenges and future directions , 2020, Annals of translational medicine.

[12]  E. Roeb,et al.  Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments , 2019, Zeitschrift für Gastroenterologie.

[13]  D. Bernstein,et al.  Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  E. Bonora,et al.  Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[15]  C. Mantzoros,et al.  Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. , 2018, Thyroid : official journal of the American Thyroid Association.

[16]  E. Bonora,et al.  Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[17]  Herbert Tilg,et al.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.

[18]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[19]  P. Kuo,et al.  Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. , 2016, Journal of clinical lipidology.

[20]  M. House,et al.  The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial , 2015, Hepatology.

[21]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[22]  Y. Chawla,et al.  Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center , 2015, Hepatology International.

[23]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[24]  E. Bonora,et al.  Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[25]  C. Catalano,et al.  Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease , 2014, Hepatology.

[26]  Y. Chawla,et al.  Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease. , 2013, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[27]  G. Musso,et al.  Association of obstructive sleep apnoea with the presence and severity of non‐alcoholic fatty liver disease. A systematic review and meta‐analysis , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[28]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[29]  James E. Nelson,et al.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[30]  K. Clément,et al.  Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. , 2012, Journal of hepatology.